Profile data is unavailable for this security.
About the company
Adocia SA is a clinical-stage biotechnology company based in France. The Company specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.
- Revenue in EUR (TTM)2.15m
- Net income in EUR-21.16m
- Incorporated2006
- Employees78.00
- LocationAdocia SA115 avenue LacassagneLYON 69003FranceFRA
- Phone+33 472610610
- Fax+33 472363967
- Websitehttps://www.adocia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Poltreg SA | 140.53k | -4.08m | 59.64m | 23.00 | -- | 3.21 | -- | 424.37 | -3.74 | -3.74 | 0.1287 | 17.04 | 0.0051 | 27.12 | 3.22 | 26,373.63 | -14.82 | -6.51 | -16.41 | -7.35 | -1,804.83 | -391.38 | -2,903.50 | -449.24 | 4.21 | -- | 0.0913 | -- | 40.04 | -- | -588.92 | -- | 214.26 | -- |
| Novacyt SA | 13.82m | -33.18m | 59.84m | 270.00 | -- | 0.5743 | -- | 4.33 | -0.4698 | -0.4781 | 0.1957 | 1.48 | 0.0843 | 2.60 | 0.4406 | 51,180.70 | -20.24 | 10.94 | -25.17 | 14.49 | 32.21 | 61.98 | -240.09 | 17.64 | 2.82 | -- | 0.1419 | -- | -44.97 | -0.9408 | -25.22 | -- | 2.09 | -- |
| Pangaea Oncology SA | 4.66m | -2.70m | 60.91m | 62.00 | -- | 2.65 | -- | 13.06 | -0.0898 | -0.0898 | 0.1557 | 0.6691 | 0.1601 | 3.86 | 1.23 | 76,449.51 | -9.46 | -11.40 | -10.90 | -14.62 | 38.92 | 79.42 | -59.10 | -57.87 | 2.57 | -- | 0.1054 | -- | -5.11 | 10.75 | -322.51 | -- | -33.46 | -- |
| Mabion SA | 32.76m | 8.76m | 63.44m | 226.00 | 7.25 | 1.86 | 5.88 | 1.94 | 2.31 | 2.31 | 8.65 | 9.01 | 0.7538 | 4.02 | 17.35 | 618,836.30 | 20.15 | -7.19 | 25.09 | -16.79 | 78.30 | 58.10 | 26.73 | -14.27 | 1.64 | 101.63 | 0.026 | -- | -7.50 | -- | 77.94 | -- | 40.86 | -- |
| BIOTON SA | 43.64m | -1.60m | 67.97m | 358.00 | -- | 0.4849 | 11.26 | 1.56 | -0.0797 | -0.0797 | 2.17 | 6.97 | 0.2303 | 1.02 | 21.19 | 520,435.80 | -0.8464 | -1.99 | -1.04 | -2.47 | 33.80 | 45.33 | -3.67 | -8.61 | 0.2085 | 0.3295 | 0.0864 | -- | -22.10 | -5.51 | 60.10 | -38.69 | 0.3284 | -- |
| Arcticzymes Technologies ASA | 9.92m | 1.25m | 75.69m | 68.00 | 60.49 | 2.78 | 42.69 | 7.63 | 0.2867 | 0.2867 | 2.27 | 6.24 | 0.3485 | 0.5349 | 6.83 | 1,706,250.00 | 4.39 | 15.58 | 4.63 | 17.22 | 94.39 | 96.69 | 12.60 | 33.23 | 17.25 | -- | 0.0298 | 0.00 | -13.16 | 12.24 | -40.89 | -- | 47.93 | -- |
| Captor Therapeutics SA | 4.37m | -10.93m | 81.03m | 104.00 | -- | 6.83 | -- | 18.56 | -10.29 | -10.29 | 4.08 | 10.87 | 0.2391 | -- | 5.26 | 179,230.80 | -59.88 | -- | -83.65 | -- | 51.97 | -- | -250.46 | -- | -- | -- | 0.1114 | -- | 44.15 | -- | -96.65 | -- | -- | -- |
| Adocia SA | 2.15m | -21.16m | 85.30m | 78.00 | -- | -- | -- | 39.67 | -1.93 | -1.93 | 0.194 | -0.4908 | 0.0774 | 2.62 | 7.44 | 27,564.10 | -76.16 | -43.08 | -396.14 | -72.93 | 7.91 | -- | -984.28 | -514.53 | 1.01 | -2.07 | 2.12 | -- | -81.22 | -46.13 | -206.65 | -- | -27.60 | -- |
| Alligator Bioscience AB | 4.02m | -20.63m | 88.24m | 51.00 | -- | -- | -- | 21.93 | -0.362 | -0.362 | 0.0696 | -0.0125 | 0.2653 | -- | 9.47 | 788,034.50 | -136.02 | -73.26 | -367.94 | -91.33 | -- | -- | -512.61 | -811.68 | -- | -35.61 | 5.17 | -- | 62.78 | 16.60 | -28.53 | -- | -20.34 | -- |
| Inventiva SA | 17.48m | -110.43m | 94.46m | 112.00 | -- | -- | -- | 5.40 | -2.45 | -2.45 | 0.3854 | -0.6146 | 0.1884 | -- | 9.18 | 156,044.60 | -116.84 | -54.30 | -207.08 | -69.98 | -- | -- | -620.31 | -669.97 | 0.9524 | -19.98 | 6.96 | -- | 43.50 | 40.46 | -103.46 | -- | -0.33 | -- |
| Anatolia TaniveBytklj Unli Ar Ge SiveTiA | 8.02m | -5.48m | 96.32m | 229.00 | -- | 2.79 | -- | 12.01 | -0.5563 | -0.5563 | 1.85 | 5.98 | 0.2549 | 0.3473 | 4.29 | 1,490,227.00 | -17.42 | 16.60 | -18.36 | 17.72 | 80.55 | 85.88 | -68.34 | 39.69 | 5.78 | -- | 0.0142 | -- | -49.14 | 72.60 | -548.82 | -- | 65.06 | -- |
| Maat Pharma SA | 2.23m | -19.72m | 102.16m | 50.00 | -- | 4.17 | -- | 45.85 | -1.73 | -1.73 | 0.196 | 1.76 | 0.0508 | 4.84 | 4.16 | 44,560.00 | -44.99 | -35.49 | -58.93 | -42.98 | 74.28 | -- | -884.96 | -1,157.54 | 2.76 | -49.61 | 0.4075 | -- | 55.80 | -- | -43.78 | -- | 30.30 | -- |
| Scope Fluidics SA | 21.78k | -5.29m | 104.71m | 40.00 | -- | 6.03 | -- | 4,807.02 | -8.29 | -8.29 | 0.0341 | 27.18 | 0.0009 | 2.94 | 0.0337 | 2,325.00 | -21.76 | 52.74 | -22.74 | 57.32 | -2,022.58 | -420.87 | -24,304.30 | 30,134.78 | 13.86 | -- | 0.0299 | -- | 27.72 | -- | -105.76 | -- | 89.99 | -- |
| Eurofins-Cerep SA | 44.07m | 7.64m | 107.94m | 228.00 | 14.13 | 1.67 | 11.23 | 2.45 | 1,514.43 | 1,514.43 | 8,743.94 | 12,820.37 | 0.5864 | 1.67 | 5.08 | 193,287.10 | 10.16 | 14.21 | 12.22 | 17.51 | 85.01 | 73.61 | 17.33 | 19.77 | 4.87 | -- | 0.00005 | -- | -7.47 | 11.60 | -33.72 | 14.64 | -- | -- |
| Heidelberg Pharma AG | 9.52m | -13.06m | 109.52m | 97.00 | -- | 2.66 | -- | 11.50 | -0.2837 | -0.2837 | 0.2062 | 0.8832 | 0.1270 | 0.194 | 13.23 | 100,234.60 | -17.42 | -43.91 | -22.34 | -64.34 | 82.74 | 52.13 | -137.16 | -206.24 | 4.90 | -- | 0.3417 | -- | -46.75 | 21.87 | -3.27 | -- | -0.8341 | -- |
Data as of Sep 20 2024. Currency figures normalised to Adocia SA's reporting currency: Euro EUR
0.34%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Uzes Gestion SAas of 30 Aug 2024 | 30.00k | 0.20% |
| CGM � Azimut Monaco SAas of 31 Jul 2024 | 20.00k | 0.13% |
| Gestys SAas of 26 Jul 2024 | 1.50k | 0.01% |
Data from 26 Jul 2024 - 30 Aug 2024Source: FactSet Research Systems Inc.
